Asset AllocatorJan 17 2024

Novo Nordisk gives DFMs' Europe picks a Danish overweight

Search supported by

Novo Nordisk gives DFMs' Europe picks a Danish overweight — Injection pens of Novo Nordisk's blockbuster weight-loss drug Wegovy (Reuters/Victoria Klesty/Illustration/File Photo)

ByJoseph Wilkins

The remarkable rise of Novo Nordisk over 2023 briefly saw the drugmaker become Europe’s most valuable company by market cap, overtaking LVMH, on the strength of its groundbreaking anti-obesity drug Wegovy.

More onAsset Allocator

Asset Allocator

May 2 2024

Allocators' UK equity picks tilts towards value

Asset Allocator Podcast

May 2 2024

Has a new spring sprung for equities?

Asset Allocator

May 2 2024

Mike Riddell walks away from Allianz Strategic Bond - like some allocators

Asset Allocator

May 1 2024

Mazars' new CIO looks to evolve the portfolios

Asset Allocator

May 1 2024

Quilter benefits from gold rush to make ad hoc rebalance

Related Topics

Asset Allocator

European equities

For unlimited access to FTAdviser content...

Register now for free

Read the latest news and views from the world of financial advice
Never miss a story - sign up to our email alerts
Bank CPD while you read

Have an account? Sign In